US 9249217
Bispecific EGFRvIII x CD3 antibody engaging molecules
granted A61KA61K2039/505A61P
Quick answer
US patent 9249217 (Bispecific EGFRvIII x CD3 antibody engaging molecules) held by The United States of America, as represented by the Secretary, DHHS expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, DHHS
- Grant date
- Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00